Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Martín, M; Pandiella, A; Vargas-Castrillón, E; Díaz-Rodríguez, E; Iglesias-Hernangómez, T; Cano, CM; Fernández-Cuesta, I; Winkow, E; Perelló, MF.

Trastuzumab deruxtecan in breast cancer

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2024; 198: [doi:10.1016/j.critrevonc.2024.104355]

Gonzalez-Cao, M; Puertolas, T; Manzano, JL; Maldonado, C; Yelamos, O; Berciano-Guerrero, MA; Cerezuela, P; Martin-Liberal, J; Muñoz-Couselo, E; Espinosa, E; Drozdowskyj, A; Berrocal, A; Soria, A; Marquez-Rodas, I; Martin-Algarra, S; Quindos, M; Puig, S.

Access to melanoma drugs in Spain: a cross-sectional survey

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(10): 2572-2583 Nº de citas: 4 [doi:10.1007/s12094-024-03501-9]

Marquez-Rodas, I; Couselo, EM; Moreno, JFR; Fernández, AMA; Guerrero, MAB; Balea, BC; Merino, LD; Arranz, EE; Castaño, AG; Jaime, AB.

SEOM-GEM clinical guidelines for cutaneous melanoma (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(11): 2841-2855 Nº de citas: 1 [doi:10.1007/s12094-024-03497-2]

Martín, M; Yoder, R; Salgado, R; del Monte-Millán, M; Alvarez, EL; Echavarria, I; Staley, JM; O'Dea, AP; Nye, LE; Stecklein, SR; Bueno, C; Jerez, Y; Cebollero, M; Bueno, O; Saenz, JAG; Moreno, F; Bohn, U; Gómez, H; Massarrah, T; Khan, QJ; Godwin, AK; López-Tarruella, S; Sharma, P.

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

CLINICAL CANCER RESEARCH. 2024; 30(10): 2160-2169 [doi:10.1158/1078-0432.CCR-24-0106]

Goetz MP; Hamilton EP; Campone M; Hurvitz SA; Cortes J; Johnston S; Llombart-Cussac A; Kaufman PA; Toi M; Jerusalem G; Graham H; Wang H; Jansen VM; Litchfield LM; Martín M.

Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer.

CLINICAL CANCER RESEARCH. 2024; 30(10): 2233-2244 Nº de citas: 1 [doi:10.1158/1078-0432.CCR-22-3573]

Sánchez-Bayona, R; de Sa, AL; Gilarranz, YJ; de Torre, AS; Alva, M; Echavarria, I; Moreno, F; Tolosa, P; Lopez, BH; de Luna, A; Lema, L; Casado, SG; Madariaga, A; López-Tarruella, S; Manso, L; Bueno-Muiño, C; Garcia-Saenz, JA; Ciruelos, E; Martin, M.

Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2-advanced breast cancer: a real-world evidence cohort

BREAST CANCER RESEARCH AND TREATMENT. 2024; 206(3): 551-559 Nº de citas: 9 [doi:10.1007/s10549-024-07324-8]

Overman, MJ; Gelsomino, F; Aglietta, M; Wong, MR; Miron, ML; Leonard, G; García-Alfonso, P; Hill, AG; Gracian, AC; Van Cutsem, E; El-Rayes, B; McCraith, SM; He, BL; Lei, M; Lonardi, S.

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

Journal for ImmunoTherapy of Cancer. 2024; 12(5): [doi:10.1136/jitc-2023-008689]

Cabezón-Gutiérrez L; Pacheco-Barcia V; Carrasco-Valero F; Palka-Kotlowska M; Custodio-Cabello S; Khosravi-Shahi P.

Update on thymic epithelial tumors: a narrative review.

Mediastinum (hong Kong, China). 2024; 8: 33-33 [doi:10.21037/med-23-47]

Goetz, MP; Cicin, I; Testa, L; Tolaney, SM; Huober, J; Guarneri, V; Johnston, SRD; Martin, M; Rastogi, P; Harbeck, N; Shahir, A; Wei, R; Andre, V; Rugo, HS; O'Shaughnessy, J.

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

Npj Breast Cancer. 2024; 10(1): Nº de citas: 8 [doi:10.1038/s41523-024-00639-1]

Martínez-Sáez, O; Cortés, J; Ciruelos, E; Marín-Aguilera, M; González, G; Paré, L; Herrera, A; Villagrasa-González, P; Prat, A; Martín, M.

Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(8): 2060-2069 Nº de citas: 5 [doi:10.1007/s12094-024-03409-4]

Valladares-Ayerbes, M; Safont, MJ; Flores, EG; García-Alfonso, P; Aranda, E; Muñoz, AML; Ferrer, EF; Nogueras, LC; Rodríguez-Salas, N; Aparicio, J; Muñoz, ML; Cáceres, PPP; Trujillo, OAC; Tocino, RV; Fernández, MS; Salud-Salvia, A; Sureda, BM; Garcia-Carbonero, R; Conesa, MAV; Vila, AL.

Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(10): 2640-2651 Nº de citas: 2 [doi:10.1007/s12094-024-03487-4]

Elez, E; Cubillo, A; Alfonso, PG; Middleton, MR; Chau, I; Alkuzweny, B; Alcasid, A; Zhang, XS; Van Cutsem, E.

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

BMC CANCER. 2024; 24(1): Nº de citas: 2 [doi:10.1186/s12885-024-12153-5]

Rodríguez-Lescure, A; Gallego, J; Garcia-Alfonso, P; Massuti, B; Marquez, R; Calvo, L; Sanchez-Rovira, P; Anton, A; Chacon, JI; Ciruelos, E; Ponce, JJ; Santaballa, A; Valladares-Ayerbes, M; Dueñas, MR; Alonso, V; Aparicio, J; Encinas, S; Robles, L; Escudero, MJ; Caballero, R; Bezares, S; de la Haba-Rodriguez, J.

Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(8): 1896-1907 [doi:10.1007/s12094-024-03411-w]

Conde, E; Hernandez, S; Carrillo, JLR; Martinez, R; Alonso, M; Curto, D; Jimenez, B; Caminoa, A; Benito, A; Garrido, P; Clave, S; Arriola, E; Esteban-Rodriguez, I; De Castro, J; Sansano, I; Felip, E; Rojo, F; Dómine, M; Abdulkader, I; Garcia-Gonzalez, J; Teixido, C; Reguart, N; Compañ, D; Insa, A; Mancheño, N; Palanca, S; Juan-Vidal, O; Baixeras, N; Nadal, E; Cebollero, M; Calles, A; Martin, P; Salas, C; Provencio, M; Aranda, I; Massuti, B; Lopez-Vilaro, L; Majem, M; Paz-Ares, L; Lopez-Rios, F.

RET Fusion Testing in Patients With NSCLC: The RETING Study

Jto Clinical And Research Reports. 2024; 5(4): Nº de citas: 3 [doi:10.1016/j.jtocrr.2024.100653]

Kim, DW; Cho, BC; Pachipala, K; Kim, SW; Wang, CL; Chang, GC; Ahn, MJ; Alvarez, R; Chiu, CH; Trigo, J; Estival, A; Karam, SD; O'Brien, C; Gowda, H; Jiang, HY; Bauman, JE.

Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study

LUNG CANCER. 2024; 190: Nº de citas: 5 [doi:10.1016/j.lungcan.2024.107530]

Caraballo, IG; Lozano, RM; Rodríguez, RJ; Alsar, JS; Morán, LO; Jiménez, MM; Martín, AJM.

Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(9): 2116-2125 Nº de citas: 1 [doi:10.1007/s12094-024-03467-8]

Martinez-Jañez, N; Ezquerra, MB; Sanchez, LMM; Carrasco, FH; Torres, AA; Morales, S; Ortega, PT; Gil, VLO; Sampedro, T; Conejero, RA; Calvo-Martinez, L; Galve-Calvo, E; López, R; de la Pena, FA; Lopez-Tarruella, S; de Araguiz, BAHF; Ruiz, LB; Cardenas, TM; Chacon, JI; Antón, FM.

First-line therapy with palbociclib in patients with advanced HR⁺/HER2^- breast cancer: The real-life study PALBOSPAIN

BREAST CANCER RESEARCH AND TREATMENT. 2024; 206(1): 57-65 Nº de citas: 5 [doi:10.1007/s10549-024-07287-w]

Rueda, AG; Taus, A; Alvarez, RA; Bernabé-Caro, R; Chara, L; López-Brea, M; Vilà, L; González, MAS; Aldagalán, ADD; Herrera, BE; Castro, RL; Cabellos, RA; Doménech, M; Falagan, S; Vega, AM; Aguado, C; Barba, A; Ureña, MTD; Isla, D; Hernández, LB; Pérez, JLF; Juan-Vidal, O; Massuti, B; Mielgo-Rubio, X; Ortega, AL; Catot, S; Dómine, M; Escoín-Pérez, C; Navalón, FG; Gil-Bazo, I; Muñoz, S; Rodríguez-Abreu, D; Roldán, RMV; Curbera, GA; León-Mateos, L; Padilla, A; Lario, AP; Sánchez-Torres, JM; Garrido, P.

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(9): 2205-2216 Nº de citas: 7 [doi:10.1007/s12094-024-03404-9]